the aid library

LIST OPTIONS

Filter

5469

Vulnerability in Myanmar: A Secondary Data Review of Needs, Coverage and Gaps

Humanitarian Assistance and Resilience Programme Facility (HARP-F) & Myanmar Information Management Unit (MIMU) (2018) C1

Based on the Vulnerability Index developed in this review, an estimated 22.7 million persons in Myanmar, or 44% of the population, were found to have some form of vulnerability related to human development and/or exposure to active conflict/violence. These people experience varying combinations of p... more

Download (118)

View PDF (142)

Strengthening and sustaining the fight against HIV and AIDS through public e- procurement - The case study of Ukraine

Transparency International Ukraine; Hivos people unlimited; Network 100percent life (2018) C2

Compiled by Tin Geber for HIVOS. London, March 2018

Download (192)

View PDF (388)

Advancing gender equality and climate action: A practical guide to setting targets and monitoring progress

Climate & Development Knowledge Network (2022) C1

Women have less access to the development services and support – such as adequate healthcare, education and modern technology – that make people more resilient to climate change and other shocks and stressors.2 Women’s unequal access to resources, their disproportionate responsibility for ca... more

Asbestos-related cancers: the‘Hidden Killer’remains a global threat

van Zandwijk, N.; Reid, G.; Frank, A. EXPERT REVIEW OF ANTICANCER THERAPY2020, VOL. 20, NO. 4, 271–278 (2020) CC2

Asbestos, the most frequent cause of occupational cancer, continues to be consumed ona massive scale, with millions of people exposed on a daily basis. This review explains why we havefailed in curtailing the silent epidemic of asbestos-related disease and why the numbers of asbestosvictims are like... more

Renewable energy solutions improve children’s health and wellbeing in Malawi

Unicef (2021) C_UNICEF

UNICEF Malawi and its partners are prioritizing renewable energy solutions for children and communities across the country to access clean and affordable electricity, with a focus on hard-to-reach, rural communities unable to access the national electricity grid.

Guidance on global monitoring for diabetes prevention and control: Framework, indicators and application

World Health Organization WHO (2024) C_WHO

The Guidance on global monitoring for diabetes prevention and control by WHO provides a comprehensive framework to support countries in tracking and managing diabetes prevention, care, and outcomes. This document outlines indicators across 4 domains: health system determinants, service delivery, ris... more

Download (2228)

View PDF (3360)

For Proper Disposal Hospital Waste

Jorge Emmanuel and Ruth Stringer Health Care Without Harm (2007)

A Global Inventory of Alternative Medical Waste Treatment Technologies

WHO aircraft disinsection methods and procedures

World Health Organization WHO (2021) C_WHO

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more